Structure Therapeutics Inc. (GPCR) Stock Score, Valuation & Financial Research

Structure Therapeutics Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for GPCR

Structure Therapeutics Inc. does not currently have a complete Wall Street Score. The stored market price is USD 27.47. These figures are a research snapshot, not a buy or sell recommendation.

What Structure Therapeutics Inc. does

Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Structure Therapeutics is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on research and development of oral small molecule therapeutics, funded primarily through equity financing and potential future licensing or collaboration agreements.

Products and services

  • The company is developing a pipeline of oral small molecule therapeutics targeting G-protein coupled receptors (GPCRs) for chronic diseases, including candidates such as GSBR-1290 and ANPA-0073.

Customer types

Healthcare providers and patients (potential future market).

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs) — The company relies on unnamed third-party CROs and CDMOs for preclinical studies, clinical trials, and the manufacturing of drug substance and drug product. Source

Competitors and product-market comparisons

  • Biopharmaceutical companies developing GPCR-targeted therapies — The company faces competition from various pharmaceutical and biotechnology companies developing therapies for metabolic and cardiovascular diseases, including those targeting GLP-1 receptors. Source

Business strengths to evaluate

  • Proprietary structure-based drug discovery and computational chemistry platform Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party manufacturers and clinical trial sites Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

GPCR financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 27.47
Market capitalization:
1.58B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -215.06M
Free cash flow:
USD -225.81M
Cash:
USD 272.64M
Total debt:
USD 6.23M
EPS:
USD -3.03

What stands out

  • Free cash flow is USD -225.81M, negative for the stored period.
  • The balance sheet shows USD 272.64M of cash versus USD 6.23M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 266.41M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for GPCR

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can GPCR fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is GPCR likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for GPCR to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of GPCR's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research GPCR

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.